Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Csl Ltd (CSL.AX)

Csl Ltd (CSL.AX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [ASX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [ASX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Csl Ltd 655 Elizabeth Street Melbourne VIC 3000 AUS

https://www.csl.com P: +61 393891911 F: +61 393891434

Description:

CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world's second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.

Key Statistics

Overview:

Market Capitalization, $K 133,121,629
Shares Outstanding, K 483,253
Annual Sales, $ 13,174 M
Annual Net Income, $ 2,194 M
% of Institutional Shareholders 34.83%

Growth:

1-Year Return -8.51%
3-Year Return 2.88%
5-Year Return 39.58%
5-Year Revenue Growth 11.67%
5-Year Earnings Growth 3.53%
5-Year Dividend Growth 9.03%

Per-Share Information:

Latest Earnings Date N/A
Earnings Per Share ttm 5.09
EPS Growth vs. Prev Year -0.06%
Annual Dividend Rate, $ 2.38
Annual Dividend Yield 1.38%
Most Recent Dividend 1.799 on 03/11/24
Next Ex-Dividends Date 03/11/24
Dividend Payable Date 04/03/24
Dividend Payout Ratio 46.74%
Most Recent Split 3-1 on 10/18/07

CSL.AX Ratios

Ratio
Price/Earnings ttm 34.71
Price/Earnings forward 30.67
Return-on-Equity % 15.05%
Return-on-Assets % 6.80%
Profit Margin % 16.65%
Debt/Equity 0.71
Price/Sales 6.20
Price/Book 4.97
Book Value/Share 55.32
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar